EcoDrugPlus

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSOSIG00000016894
Gene Symbol: PSMB7
1 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSOSIG00000007131
Gene Symbol: PSMB9A
1 Cross references
182 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSOSIG00000014267
Gene Symbol: PSMB9A
1 Cross references
201 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSOSIG00000013518
Gene Symbol: PSMD2
1 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4a

Ensembl ID : ENSOSIG00000001050
Gene Symbol: PSMD4A
1 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4b

Ensembl ID : ENSOSIG00000011829
Gene Symbol: PSMD4B
1 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1a

Ensembl ID : ENSOSIG00000017265
Gene Symbol: PSMC1A
1 Cross references
281 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSOSIG00000023999
Gene Symbol: PSMC2
1 Cross references
232 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSOSIG00000010710
Gene Symbol: PSMC3
1 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSOSIG00000007260
Gene Symbol: PSMC5
1 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSOSIG00000013133
Gene Symbol: PSMC6
1 Cross references
242 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSOSIG00000009258
Gene Symbol: PSMD1
1 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).